<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747964</url>
  </required_header>
  <id_info>
    <org_study_id>STSP-0601-01</org_study_id>
    <nct_id>NCT04747964</nct_id>
  </id_info>
  <brief_title>A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor</brief_title>
  <official_title>A Phase 1,Multi-center, Randomized, Open, Single-dose Escalation Design to Evaluate the Safety, Tolerability and Pharmacodynamics of STSP-0601 for Injection in Patients With Inhibitory Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson (Beijing) Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Staidson (Beijing) Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at five dose&#xD;
      levels. The results will help identify the most optimal doses to treat bleedings in&#xD;
      hemophilia patients with inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects of adverse events</measure>
    <time_frame>Baseline to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects With Significant Abnormal Physical Examination</measure>
    <time_frame>Baseline to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects of Significant Abnormal Vital Signs Findings</measure>
    <time_frame>Baseline to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Significant Abnormal Laboratory Values</measure>
    <time_frame>Baseline to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects With Significant Abnormal Electrocardiography (ECG) Findings</measure>
    <time_frame>Baseline,1 hour,4 hour,48 hour,Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Baseline to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin production (TG) peak</measure>
    <time_frame>Baseline to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>A single lowest dose of treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A single low dose of treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A single intermediate dose of treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A single high dose of treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A single highest dose of treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSP-0601 for Injection</intervention_name>
    <description>Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements</description>
    <arm_group_label>A single lowest dose of treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSP-0601 for Injection</intervention_name>
    <description>Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements</description>
    <arm_group_label>A single low dose of treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSP-0601 for Injection</intervention_name>
    <description>Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements</description>
    <arm_group_label>A single intermediate dose of treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSP-0601 for Injection</intervention_name>
    <description>Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements</description>
    <arm_group_label>A single high dose of treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSP-0601 for Injection</intervention_name>
    <description>Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements</description>
    <arm_group_label>A single highest dose of treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old ≤age≤65 years of age,male.&#xD;
&#xD;
          -  Hemophilia A or B patients with inhibitors.&#xD;
&#xD;
          -  Peak historical inhibitor titer ≥ 5 BU and a positive inhibitor test when enrolled.&#xD;
&#xD;
          -  Establish proper venous access.&#xD;
&#xD;
          -  Provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any coagulation disorder other than hemophilia A or B.&#xD;
&#xD;
          -  Treat with prophylactic treatment of coagulation factor.&#xD;
&#xD;
          -  Treat with anticoagulant within 7d of the time of study drug administration.&#xD;
&#xD;
          -  Have an active, ongoing bleeding for which the patient is being treated, or treatment&#xD;
             for a bleeding was stopped within 7d of the time of study drug administration.&#xD;
&#xD;
          -  Have a history of arterial and/or venous thromboembolic events.&#xD;
&#xD;
          -  Have platelet count &lt;100,000/mL.&#xD;
&#xD;
          -  Severe liver or kidney disease.&#xD;
&#xD;
          -  Accept major operation or blood transfusion within 1 month of the time of screening.&#xD;
&#xD;
          -  HIV antibody positive.&#xD;
&#xD;
          -  Have a known allergy to Blood product.&#xD;
&#xD;
          -  Participate in other clinical research within 1 month of the time of study drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanli Wang</last_name>
    <phone>13811864434</phone>
    <email>wangyanli@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhang</last_name>
      <phone>+86 022 23909095</phone>
      <email>ec@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

